Adagene Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
128
- Stock Symbol
-
ADAG
- Share Price
-
$1.71
- (As of Friday Closing)
Adagene General Information
Description
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
Contact Information
Website
www.adagene.comCorporate Office
- 4 Floor, Building C14 Number 218
- Xinghu Street, Suzhou Industrial Park
- Suzhou, Jiangsu
- China
Corporate Office
- 4 Floor, Building C14 Number 218
- Xinghu Street, Suzhou Industrial Park
- Suzhou, Jiangsu
- China
Adagene Stock Performance
As of 13-Nov-2026, Adagene’s stock price is $1.71. Its current market cap is $115M with 67.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.71 | $2.00 | $1.50 - $4.85 | $115M | 67.1M | 266K | -$0.38 |
Adagene Financials Summary
As of 30-Jun-2026, Adagene has a trailing 12-month revenue of $9.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 225,794 | 33,100 | 13,216 | (18,859) |
| Revenue | 9,291 | 7,671 | 103 | 18,111 |
| EBITDA | (22,514) | (19,158) | (35,452) | (19,222) |
| Net Income | (20,511) | (17,609) | (33,424) | (18,946) |
| Total Assets | 133,576 | 78,263 | 89,268 | 115,729 |
| Total Debt | 6,091 | 6,263 | 18,494 | 22,307 |
Adagene Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adagene Comparisons
Industry
Financing
Details
Adagene Competitors (32)
One of Adagene’s 32 competitors is Editas Medicine, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Editas Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Alphamab Oncology | Formerly VC-backed | Suzhou, China | ||||
| Integrated DNA Technologies | Formerly PE-Backed | Coralville, IA | ||||
| GeneTex | Formerly VC-backed | Irvine, CA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX |
Adagene Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Adagene Patents
Adagene Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12781391-B2 | Dynamic human antibody light chain libraries | Active | 11-Jan-2023 | ||
| EP-4323001-A1 | Combination therapies for treating cancer | Pending | 11-Apr-2021 | ||
| EP-4323001-A4 | Combination therapies for treating cancer | Pending | 11-Apr-2021 | ||
| US-20240209092-A1 | Combination therapies for treating cancer | Pending | 11-Apr-2021 | ||
| WO-2022218264-A1 | Combination therapies for treating cancer | Inactive | 11-Apr-2021 | A61P35/00 |
Adagene Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Adagene Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adagene FAQs
-
When was Adagene founded?
Adagene was founded in 2011.
-
Where is Adagene headquartered?
Adagene is headquartered in Suzhou, China.
-
What is the size of Adagene?
Adagene has 128 total employees.
-
What industry is Adagene in?
Adagene’s primary industry is Drug Discovery.
-
Is Adagene a private or public company?
Adagene is a Public company.
-
What is Adagene’s stock symbol?
The ticker symbol for Adagene is ADAG.
-
What is the current stock price of Adagene?
As of 13-Nov-2026 the stock price of Adagene is $1.71.
-
What is the current market cap of Adagene?
The current market capitalization of Adagene is $115M.
-
What is Adagene’s current revenue?
The trailing twelve month revenue for Adagene is $9.3M.
-
Who are Adagene’s competitors?
Editas Medicine, Alphamab Oncology, Integrated DNA Technologies, GeneTex, and Rein Therapeutics are some of the 32 competitors of Adagene.
-
What is Adagene’s annual earnings per share (EPS)?
Adagene’s EPS for 12 months was -$0.38.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
